ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...

B-cell therapy for multiple sclerosis (MS) was first approved in 2017, after the anti-CD20 agent ocrelizumab (Ocrevus) demonstrated its ability to strongly suppress the acute inflammatory activity and ...

Novartis AG (NYSE:NVS) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 24, ...

Most relapsing MS patients on Mavenclad did not have confirmed disability progression for at least four years, new Phase 4 ...